Day: November 29, 2022

COLLINGWOOD, Ontario, Nov. 29, 2022 (GLOBE NEWSWIRE) — The Limestone Boat Company Limited (the “Company”) (TSXV: BOAT | OTCQB: LMSBF) – owner and builder of Aquasport Boats, Limestone® Boats and Boca Bay Boats – today reports its financial results for the three and nine months ended September 30, 2022 (“Q3 FY 2022″). All dollar amounts are in Canadian dollars unless otherwise noted. The Company’s complete Financial Statements and Management Discussion and Analysis for the three and nine months ended September 30, 2022 are available at www.sedar.com or on the Company’s website at www.limestoneboatcompany.com. Limestone has started to see the effects of management decisions taken in Q2 2022 concerning wholesale pricing and labour realignment with improvements in margin. These are attributable, in large part, to price increases...

Post-quarter end, launched a refreshed version of the Company’s award-winning app for psychedelic guidance, renamed ‘Field Trip’, to include a number of new features, such as offline access to music and meditations, higher bit-rate streaming and access to Field Trip’s therapeutic programs. In November, announced ‘Freedom by Field Trip™’, a first-of-its-kind, one-year hybrid ketamine therapy program blending psychedelic-assisted therapies with holistic wellness support to offer people the ability to participate in ketamine therapy at-home or in one of Field Trip’s locations. Post-quarter end, strengthened leadership team with the appointment of Stacey Hoisak as Senior Vice President, General Counsel, and Dr. Monique Moller as Vice President, Integrative Health. Field Trip generated revenues of $1.8 million during the quarter ended...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) — Water Ways Technologies Inc. (TSXV: WWT) (FRA: WWT) (“Water Ways” or the “Company“), a global provider of Israeli-based agriculture technology, providing water irrigation solutions to agricultural producers, announces the filing of its Interim Financial Statements (the “Statements“) and Managements Discussion and Analysis (the “MD&A“) for the three and nine months periods ended September 30, 2022. A comprehensive discussion of Water Ways’ financial position and results of operations is provided in the MD&A, filed on SEDAR (www.sedar.com) Mr. Ohad Haber, CEO and Chairman of the Board of Water Ways states: “We are continuing to build and grow...

Consolidated fourth quarter Sales of $140.4 million compared to $106.4 million in the prior year Quarterly Net Income of $5.6 million and EPS of $0.14 EBITDA of $16.5 million compared to $15.3 million in the prior year quarter Growth strategy continues with $52.7 million in capital spending and $57.6 million in cash deployed for the Halex acquisition in fiscal 2022.    Quarterly dividend of $0.105 per common share to be paid December 30, 2022TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) — Exco Technologies Limited (TSX-XTC, OTCQX-EXCOF) today announced results for its fourth quarter and year ended September 30, 2022. In addition, Exco announced a quarterly dividend of $0.105 per common share which will be paid on December 30, 2022 to shareholders of record on December 16, 2022. The dividend is an “eligible dividend” in accordance...

–Updated Data on Phase 1/2 Trial Evaluating PORT-2 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting– –Clinical Collaboration Agreement Entered into with Merck for Evaluation of PORT-2 in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with first-line and refractory non-small cell lung cancer (NSCLC)– —Focused Clinical Development Goals on Producing Nine Phase 1b/Phase 2 Data Readouts in Multiple Tumor Types Over the Next Two Years– WESTPORT, Conn., Nov. 29, 2022 (GLOBE NEWSWIRE) — Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results...

NEWS RELEASE – INSIDE AND REGULATED INFORMATION29 NOVEMBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Provides Business Update IRVINE, CA, and HERSTAL, BELGIUM – November 29, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided clinical and reimbursement product developments, updated guidance for 2022, and initial guidance for 2023. Select mdx reimbursement update Under the foundational LCD (Local Coverage Decision) process recently implemented by the Molecular Diagnostics Services (MolDX) Program administered by Palmetto GBA, all tests within an LCD-covered indication must submit a Technical Assessment (TA) for review and consideration. The indication for use of Select mdx is covered by Medicare’s foundational LCD Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for...